+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

Results for tag: "Tumor Suppressor"

From
Neuroblastoma - Pipeline Insight, 2024 - Product Thumbnail Image

Neuroblastoma - Pipeline Insight, 2024

  • Clinical Trials
  • April 2024
  • 80 Pages
  • Global
From
Cutaneous Squamous Cell Carcinoma - Pipeline Insight, 2024 - Product Thumbnail Image

Cutaneous Squamous Cell Carcinoma - Pipeline Insight, 2024

  • Drug Pipelines
  • April 2024
  • 120 Pages
  • Global
From
Proteasome inhibitors - Pipeline Insight, 2024 - Product Thumbnail Image

Proteasome inhibitors - Pipeline Insight, 2024

  • Clinical Trials
  • January 2024
  • 60 Pages
  • Global
From
TGFb inhibitors - Pipeline Insight, 2024 - Product Thumbnail Image

TGFb inhibitors - Pipeline Insight, 2024

  • Clinical Trials
  • January 2024
  • 60 Pages
  • Global
From
From
PI3K inhibitors - Pipeline Insight, 2024 - Product Thumbnail Image

PI3K inhibitors - Pipeline Insight, 2024

  • Clinical Trials
  • January 2024
  • 150 Pages
  • Global
From
Proto-oncogene protein c mdm2 inhibitors - Pipeline Insight, 2024 - Product Thumbnail Image

Proto-oncogene protein c mdm2 inhibitors - Pipeline Insight, 2024

  • Drug Pipelines
  • January 2024
  • 60 Pages
  • Global
From
P53 Antigen Modulators - Pipeline Insight, 2024 - Product Thumbnail Image

P53 Antigen Modulators - Pipeline Insight, 2024

  • Drug Pipelines
  • January 2024
  • 60 Pages
  • Global
From
Cyclin-Dependent Kinase Inhibitor - Pipeline Insight, 2024 - Product Thumbnail Image

Cyclin-Dependent Kinase Inhibitor - Pipeline Insight, 2024

  • Drug Pipelines
  • March 2024
  • 180 Pages
  • Global
From
From
Precision Cancer Therapeutics, 2022 - Product Thumbnail Image

Precision Cancer Therapeutics, 2022

  • Report
  • November 2022
  • 154 Pages
  • Global
From
Selinexor - Product Thumbnail Image

Selinexor

  • Report
  • October 2018
  • 32 Pages
  • Global
From
Cellular Tumor Antigen p53 - Pipeline Review, H2 2019 - Product Thumbnail Image

Cellular Tumor Antigen p53 - Pipeline Review, H2 2019

  • Drug Pipelines
  • December 2019
  • 134 Pages
  • Global
From
Wilms Tumor Protein (WT33 or WT1) - Pipeline Review, H2 2019 - Product Thumbnail Image

Wilms Tumor Protein (WT33 or WT1) - Pipeline Review, H2 2019

  • Drug Pipelines
  • December 2019
  • 80 Pages
  • Global
From
From
Serine/Threonine Protein Kinase ATR - Pipeline Review, H1 2020 - Product Thumbnail Image

Serine/Threonine Protein Kinase ATR - Pipeline Review, H1 2020

  • Drug Pipelines
  • February 2020
  • 65 Pages
  • Global
From
Serine Threonine Protein Kinase ATR - Pipeline Review, H2 2019 - Product Thumbnail Image

Serine Threonine Protein Kinase ATR - Pipeline Review, H2 2019

  • Drug Pipelines
  • December 2019
  • 63 Pages
  • Global
From
Loading Indicator

Tumor suppressor drugs are a type of oncology drug used to treat cancer. They work by inhibiting the growth of cancer cells, either by blocking the growth of new cells or by killing existing cells. Tumor suppressors are typically used in combination with other treatments, such as chemotherapy or radiation therapy, to maximize the effectiveness of the treatment. They are also used to reduce the risk of recurrence of cancer after treatment. Tumor suppressors are typically administered orally or intravenously, depending on the type of cancer being treated. Common side effects of tumor suppressors include nausea, vomiting, fatigue, and hair loss. The tumor suppressor market is a rapidly growing segment of the oncology drug market. As the number of cancer cases continues to rise, the demand for effective treatments is increasing. This has led to an increase in research and development of new tumor suppressor drugs, as well as the development of new delivery methods. Some companies in the tumor suppressor market include Novartis, Merck, Pfizer, and AstraZeneca. Show Less Read more